Edition:
India

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

216.45CHF
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
CHF216.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,898,921
52-wk High
CHF255.00
52-wk Low
CHF206.35

Latest Key Developments (Source: Significant Developments)

FDA Approves Abbvie & Genentech USA's VENCLEXTA For Treating Two Types Of Blood Cancers
Friday, 8 Jun 2018 

June 8 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS APPROVED ABBVIE & GENENTECH USA'S VENCLEXTA FOR TREATING PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA.  Full Article

Five Prime Therapeutics Announces Collaboration With Roche
Thursday, 31 May 2018 

May 30 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP COMPANION DIAGNOSTICS FOR TARGETED IMMUNO-ONCOLOGY INVESTIGATIONAL DRUG CANDIDATES.FIVE PRIME THERAPEUTICS INC - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED..  Full Article

Genentech's Announces results from Phase III Haven 3 study evaluating Hemlibra prophylaxis
Monday, 21 May 2018 

May 21 (Reuters) - :GENENTECH'S HEMLIBRA (EMICIZUMAB-KXWH) REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS.GENENTECH - HEMLIBRA REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS.GENENTECH- DATA FROM BOTH HAVEN 3 AND HAVEN 4 STUDIES ARE BEING SUBMITTED TO HEALTH AUTHORITIES AROUND WORLD FOR APPROVAL CONSIDERATION.  Full Article

FDA Issues Alert On Use Of Keytruda/Tecentriq For Patients With Urothelial Cancer, Have Low Expression Of PD-L1
Friday, 18 May 2018 

May 18 (Reuters) - FDA::U.S. FDA - ISSUES ALERT ABOUT DECREASED SURVIVAL ASSOCIATED WITH THE USE OF KEYTRUDA (PEMBROLIZUMAB) OR TECENTRIQ (ATEZOLIZUMAB).U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ.FDA - MERCK, GENENTECH HAVE STOPPED ENROLLING PATIENTS WHOSE TUMORS HAVE PD-L1 LOW STATUS TO KEYTRUDA/TECENTRIQ MONOTHERAPY ARMS PER DMCS’ RECOMMENDATIONS.U.S. FDA SAYS MONOTHERAPY ARMS REMAIN OPEN ONLY TO PATIENTS WHOSE TUMORS HAVE PD-L1 HIGH STATUS.U.S. FDA - COMBINATION ARMS AND THE CHEMOTHERAPY ARMS OF BOTH STUDIES ALSO REMAIN OPEN.FDA - ISSUED ALERT ON KEYTRUDA/TECENTRIQ AS MONOTHERAPY FOR PATIENTS WITH UROTHELIAL CANCER WHO HAVE NOT RECEIVED PRIOR THERAPY, HAVE LOW EXPRESSION OF PD-L1.  Full Article

Genentech Says In Phase 3 Impower150 Study, Survival Advantage For Tecentriq-Avastin Combo Was Seen In All Exploratory Patient Subgroups Analyzed
Thursday, 17 May 2018 

May 16 (Reuters) - GENENTECH::PHASE III IMPOWER150 STUDY SHOWED GENENTECH’S TECENTRIQ AND AVASTIN PLUS CARBOPLATIN AND PACLITAXEL HELPED PEOPLE WITH A SPECIFIC TYPE OF METASTATIC LUNG CANCER LIVE SIGNIFICANTLY LONGER COMPARED TO AVASTIN PLUS CARBOPLATIN AND PACLITAXEL.GENENTECH - IN PHASE III IMPOWER150 STUDY, SURVIVAL ADVANTAGE FOR TECENTRIQ-AVASTIN COMBO REGIMEN WAS SEEN IN ALL EXPLORATORY PATIENT SUBGROUPS ANALYZED.  Full Article

FDA Accepts Turnstone Biologics' IND For Cancer Immunotherapy
Wednesday, 16 May 2018 

May 16 (Reuters) - Turnstone Biologics::TURNSTONE BIOLOGICS ANNOUNCES U.S. FDA ACCEPTANCE OF IND FOR IMMUNOTHERAPY TARGETING HPV POSITIVE CANCERS.TURNSTONE BIOLOGICS ANNOUNCES U.S. FDA ACCEPTANCE OF IND FOR IMMUNOTHERAPY TARGETING HPV POSITIVE CANCERS.TURNSTONE BIOLOGICS - ENTERED INTO A CLINICAL SUPPLY AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD UNDER WHICH ROCHE WILL PROVIDE ATEZOLIZUMAB (TECENTRIQ).  Full Article

FDA Approves Additional Claim For Roche Cobas Zika Test
Monday, 14 May 2018 

May 14 (Reuters) - Roche Holding AG ::FDA APPROVES ADDITIONAL CLAIM FOR ROCHE COBAS ZIKA TEST.NEW CLAIM ALLOWS FOR STREAMLINED SCREENING OF POOLED BLOOD OR PLASMA DONATIONS.  Full Article

Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Zealand Pharma A/S - Co Is Responsible For Conducting Phase 3 Trials, While Roche Diabetes Care Provides Its Accu ::ZEALAND AND ROCHE DIABETES CARE ENTER PHASE 3 STUDY COLLABORATION FOR TREATMENT OF CONGENITAL HYPERINSULINISM WITH DASIGLUCAGON.SURGICAL TREATMENT FOR CHILDREN WITH CHI.PHASE 3 TRIALS OF DASIGLUCAGON ARE SET TO START IN SECOND HALF OF 2018.CHEK COMBO PUMP SYSTEM FOR STUDY.  Full Article

Inception Neuroscience Program Acquired By Roche
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Roche Holdings Inc [RIC:RIC:ROGUS.UL]::INCEPTION NEUROSCIENCE PROGRAM ACQUIRED BY ROCHE.‍VERSANT VENTURES SAYS FINANCIAL TERMS ARE NOT DISCLOSED​.  Full Article

Roche Says Completes Acquisition Of Flatiron Health
Friday, 16 Feb 2018 

April 6 (Reuters) - Roche Holding AG ::SAYS COMPLETES ACQUISITION OF FLATIRON HEALTH.  Full Article

Deals of the day-Mergers and acquisitions

June 19 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday: